Evidence map›Paper›PMID 34336009›Full record

ReviewDisease markers2021

Ischemia-Modified Albumin: Origins and Clinical Implications.

Alla Shevtsova, Iuliia Gordiienko, Viktoriia Tkachenko, Galyna Ushakova

Open access · hybridAbstract readReview
In one paragraph

Review in Disease markers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed, 4 pooled it
7.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

67 citing papers in PubMed, 4 syntheses or guidelines pooled it, 125 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Article
  7. Article
  8. Article
  9. Observational
  10. Article
  11. Advances in biomarkers for myocardial injury after non-cardiac surgery.Journal of anesthesia and translational medicine · 2026
    Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Observational

7 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Alla ShevtsovaOles Honchar Dnipro National University, 72 Gagarin Ave, Dnipro 49010, Ukraine.ORCID https://orcid.org/0000-0003-0409-6030
Iuliia GordiienkoDnipro State Medical University, 9 Vernadsky Str., Dnipro 49044, Ukraine.ORCID https://orcid.org/0000-0003-0788-2176
Viktoriia TkachenkoDnipro State Medical University, 9 Vernadsky Str., Dnipro 49044, Ukraine.ORCID https://orcid.org/0000-0003-2231-2913
Galyna UshakovaOles Honchar Dnipro National University, 72 Gagarin Ave, Dnipro 49010, Ukraine.ORCID https://orcid.org/0000-0002-5633-2739
Dnipro State Medical University · UAOles Honchar Dnipro National University · UA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Albumin is one of the most abundant proteins in the body of mammals: about 40% of its pool is located in the intravascular space and the remainder is found in the interstitial space. The content of this multifunctional protein in blood is about 60-65% of total plasma proteins. A decrease in its synthesis or changes of functional activity can destabilize oncotic blood pressure, cause a violation of transporting hormones, fatty acids, metals, and drugs. Albumin properties change under ischemic attacks associated with oxidative stress, production of reactive oxygen species, and acidosis. Under these conditions, ischemia-modified albumin (IMA) is generated that has a reduced metal-binding capacity, especially for transition metals, such as copper, nickel, and cobalt. The method of determining the cobalt-binding capability of HSA was initially proposed to evaluate IMA level and then licensed as an ACB test for routine clinical analysis for myocardial ischemia. Subsequent studies have shown the viability of the ACB test in diagnosing other diseases associated with the development of oxidative stress. This review examines recent data on IMA generation mechanisms, describes principles, advantages, and limitations of methods for evaluation of IMA levels, and provides detailed analysis of its use in diagnostic and monitoring therapeutic efficacy in different diseases.

Indexed as

AlbuminsBiomarkersHumansIschemiaAlbuminsBiomarkers

Identifiers

PMID34336009
PMCPMC8315882
OpenAlexW3185320847

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.